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Abstract 
Human papillomavirus (HPV) is the most common sexually transmitted disease in the 
United States. Despite most common transmission, HPV immunization in adolescents 
remains below target rates of 80% as outlined by Healthy People 2020 Objectives. Nearly 
all individuals will contract HPV during their lifetime. The purpose of this project was to 
educate providers on successfully promoting HPV immunization in adolescents utilizing 
evidence-based methods. The health belief model (HBM) was the theoretical 
underpinning utilized to teach providers on discussions about 9vHPV immunization with 
parents of adolescents. The practice focused question explored whether an education 
program using concepts from the HBM would increase provider perception of 
preparedness on recommending Gardasil 9 immunization in adolescents. Convenience 
sampling was utilized to recruit participants. There were 9 out of 25 providers that 
attended the educational in service with 8 completing the continuing education evaluation 
tool. Participants included providers who are affiliated and hold privileges with the health 
care system. Survey Monkey was used to analyze the participant evaluations. All the 
participants found the educational information relevant to increasing their perception of 
preparedness on recommending Gardasil 9 immunization in adolescents. The findings 
suggest that providers would benefit from training on recommending HPV immunization 
in adolescents. Continued training would help enhance timely immunization rates that 
could decrease cancer rates and reduce associated healthcare cost, in turn promoting 
population health and positive social change.  
  
 
 
Addressing Human Papillomavirus Vaccination in Primary Care Pediatrics 
by 
Natasha Marie Subramaniam 
 
MS, Walden University, 2014 
BS, Indiana Wesleyan University, 2011 
 
 
Project Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Nursing Practice 
 
 
Walden University 
[August] 2019 
  
Dedication 
In dedication to my three sons, Tavish, Ranesh, and Gyan, and to my loving 
husband, Kumar. Each of you has been pivotal in my success as a nurse and scholar. 
Thank you for always believing in me and inspiring me in all I do!  I love you all! 
  
Acknowledgments 
I would like to acknowledge the following individuals for their contributions in 
my education. First and foremost, I thank God for all he has done in my life and blessed 
me with. Secondly, I thank my family for their endless sacrifices throughout my 
educational pursuit, each of your sacrifices have not went unnoticed. I love you all so 
much!  A special thanks to, to Dr. Anthony Henry, Dr. Jim Ingram, and Dr. Mark Souder 
for each of your contributions and advice throughout this journey; Each of you have 
played a pivotal role in my success. Thank you, Sarah Schultis, RN, Cheryl Jones, RN, 
Lori Hollenbaugh, RN, and Nicole Smith, LPN for cheering me on throughout all of my 
educational pursuits and being such dear friends. Thank you to Dr. Barrett for all your 
help in getting me through this program!  We have spent countless hours discussing my 
capstone and without your dedication to teaching and the nursing profession, I would not 
be here. A special thanks to Dr. Eileen Fowles, Dr. Nguh, Dr. McGinnis, and the adjunct 
faculty at Walden University. 
 
 i 
Table of Contents 
List of Tables .......................................................................................................................v 
List of Figures .................................................................................................................... vi 
Section 1: Nature of the Project ...........................................................................................1 
Introduction ....................................................................................................................1 
Problem Statement .........................................................................................................5 
Purpose ...........................................................................................................................6 
Addressing the Gap in Practice ............................................................................... 7 
Nature of Doctoral Project .............................................................................................8 
Significance....................................................................................................................9 
Stakeholders ............................................................................................................ 9 
Contribution to Nursing Practice .......................................................................... 10 
Generalizability ..................................................................................................... 11 
Implications for Social Change ............................................................................. 11 
Summary ......................................................................................................................12 
Section 2: Background and Context ..................................................................................13 
Introduction ..................................................................................................................13 
Concepts, Models, and Theories ..................................................................................15 
Theoretical Concepts and Models ......................................................................... 15 
Definition of Key Terms ..............................................................................................21 
Relevance to Nursing Practice .....................................................................................23 
Practice Problem ................................................................................................... 25 
 ii 
Practice Recommendations ................................................................................... 26 
Local Background and Context ...................................................................................29 
Institutional Context.....................................................................................................30 
Federal Context ............................................................................................................31 
Role of the DNP Student..............................................................................................32 
Professional Context ............................................................................................. 32 
Motivation for Project ........................................................................................... 33 
Biases 34 
Role of the Project Team .............................................................................................34 
Summary ......................................................................................................................36 
Section 3: Collection and Analysis of Evidence ................................................................37 
Introduction ..................................................................................................................37 
Practice-Focused Question...........................................................................................37 
Aligning Practice with Purpose ...................................................................................38 
Sources of Evidence .....................................................................................................39 
Appraisal of Evidence ........................................................................................... 41 
Evidence Generated for Doctoral Project. ...................................................................41 
Participants ............................................................................................................ 42 
Procedures ............................................................................................................. 43 
Protections............................................................................................................. 47 
Analysis and Synthesis ................................................................................................48 
Analysis Procedures .............................................................................................. 49 
 iii 
Summary ......................................................................................................................50 
Section 4: Findings and Recommendations .......................................................................51 
Introduction ..................................................................................................................51 
Sources of Evidence .....................................................................................................51 
Findings and Implications ............................................................................................52 
Unanticipated Limitations ............................................................................................55 
Implications..................................................................................................................58 
Recommendations ........................................................................................................59 
Contribution of the Doctoral Project Team .................................................................61 
Process .................................................................................................................. 61 
Plans 61 
Strength and Limitations of the Project .......................................................................62 
Strengths ............................................................................................................... 62 
Limitations ............................................................................................................ 63 
Recommendations ........................................................................................................65 
Section 5: Dissemination Plan ...........................................................................................66 
Analysis of Self ............................................................................................................66 
Completion ...................................................................................................................68 
Summary ......................................................................................................................69 
References ..........................................................................................................................72 
Appendix A: Continuing Education Evaluation Tool ........................................................84 
Appendix B: Power Point Teaching Tool ..........................................................................85 
 iv 
Appendix C: Teaching Tools Provided for Providers During Inservice ............................94 
 
 
 v 
List of Tables 
Table 1. Health Belief Model Applied to Immunization ...................................................16 
Table 2. Educational Intervention Discussion Points  ................................……………...46 
 
 
 vi 
List of Figures 
Figure 1. Evidence based pyramid of research ..................................................................19 
Figure 2. Continuing education evaluation tool responses on Likert Scale……………...54 
 
1 
 
Section 1: Nature of the Project 
Introduction 
Human papillomavirus (HPV) is the most common sexually transmitted disease in 
the United States (Grabiel et al., 2013). Researchers have identified more than 200 
species of HPV, with 40 types being spread through sexual contact (National Cancer 
Institute, 2018). Nearly half of all HPV infections are with high risk or oncogenic strains, 
resulting in 5% of all cancers worldwide (National Cancer Institute, 2018). These high-
risk HPV infections are well-known among researchers as cancer causing viral infections 
(National Cancer Institute, 2018). While it is difficult to assess the lifetime prevalence 
rates of HPV, existing data suggests that the rates range between 79% and 100% 
(Chesson, Dunne, Hariri, and Markowitz, 2015; National Cancer Institute, 2018).  
“High risk” HPVs cause several types of cancer. Virtually all cases of cervical 
cancer are caused by HPV, and just two HPV types, 16 and 18, are responsible for about 
70% of all cases. (National Cancer Institute, 2015). HPV Type 16 is associated with 
causing most anal cancers, with 95% of these cancers resulting from HPV infection 
(National Cancer Institute, 2018). HPV Type 16 infection is also a well-known risk factor 
for oropharyngeal cancers; with nearly 70% of these cancers resulting from HPV 
infection (National Cancer Institute, 2015). Less frequent occurring cancers that result 
from infection with high risk HPV include vaginal (65%), vulvar (50%), and penile 
cancer (35%) (National Cancer Institute, 2018).  
Cervarix was the first vaccine to protect against HPV Types 16 and 18 (Mulcahy, 
2016) and was released by GlaxoSmithKline (GSK) in 2009 (Brookes, 2016). Cervarix is 
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still available outside of the U.S. marketplace, with indications for use in females 9-45 
years of age (Cervarix, Human Papillomavirus Vaccine Types 16 and 18 [Recombinant, 
AS04 adjuvanted] Consumer Medicine Information, n.d.). Gardasil (Human 
Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine Recombinant) released 
by Merck in 2006 is recommended for routine immunization against females only 
(Brookes, 2016). Despite each vaccine touting cancer prevention, the focus always 
remained on cervical cancer, which led to the feminization of the vaccines and impacted 
the public’s perception of benefit to this recommended immunization (Daley et al., 2017). 
With Gardasil 9 (9vHPV) superseding Gardasil (4vHPV) immunization through inclusion 
of an additional five strains of HPV, Gardasil production ceased, leaving Gardasil 9 as 
the only HPV immunization on the U.S. market (Henry J. Kaiser Family Foundation, 
2018). The various vaccine options, differing immunization schedules, the novelty of the 
vaccine(s), gender seclusion, and manufacturer updates further contributed to delayed 
recommendations for the vaccine(s) and the public’s perceived benefits to immunization.  
Oncogenic HPV strains were first identified as the cause of cervical cancer in the 
late 1970s (Faridi, Zahara, Khan, Idress, 2011). However, as cancer research emerges, 
researchers have learned that HPV viruses also have oncogenic propensity in males as 
well (Fardi et al., 2011). It was not until 2010 that Gardasil extended its labeling to 
include immunization against males (Brookes, 2016). With further research and 
advancements, Gardasil 9 entered the U.S. market in 2014 with indications for both males 
and females (Brookes, 2016). Today, Gardasil 9 is the only immunization that remains 
available for use in the United States and is indicated for protection against cervical, 
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vaginal, anal, and penile cancers linked to HPV infection females and males (Mulcahy, 
2016). There is new research that suggest it also offers protection against many 
oropharyngeal cancers as well (Centers for Disease Control and Prevention [CDC], 
2018a), though the package insert has not yet been updated to reflect this. After Merck 
introduced Gardasil 9 with broader recommendations for coverage, Cervarix was 
discontinued for use in the United States in 2016 (Mulcahy, 2016). 
In 2013, 37.6% of eligible females and only 13.9% of males received the full 
series of Gardasil 9 vaccines (Lu et al., 2015; Roberts et al., 2015). As of 2016, over half 
of adolescents have started the HPV vaccination series (Perkins, 2017). However, this is 
below Healthy People 2020 target goals of 80% of adolescents having received the entire 
immunization series (Office of Disease Prevention and Promotion [ODPP], 2017). The 
statistics reflected by Lu et al. (2015) as well as Roberts et al. (2015) represent data like 
that of a local health care system where the teaching project occurred. This health care 
system has HPV immunization rates estimated at 14% in both males and females, 9-14 
years of age. The data represents both partial and completed series spanning across 
4vHPV and 9vHPV immunizations. 
Frazer noticed that cervical cancer and anal cancers were directly linked to human 
papillomavirus infections (Gavi, the Vaccine Alliance, 2019). Frazer began creating a 
vaccine in hopes of eliminating these preventable cancers in the 1980s (Gavi, the Vaccine 
Alliance, 2019). By 2006, Frazer had developed an HPV vaccine and saw the vaccine 
make it through clinical trials and be applied to a population in Australia (Gavi, the 
Vaccine Alliance, 2019). Frazer believed that immunology from vaccinations is the next 
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greatest advancement in population health after clean water, as it yields the potential to 
save lives from preventable diseases (Gavi, the Vaccine Alliance, 2019). 
The HPV vaccine protects individuals from nine of the most common sexually 
transmitted strains of HPV. Early vaccination, before sexual debut is key to HPV cancer 
prevention (American Academy of Pediatrics [AAP], n.d.a). Merck, as well as the 
American College of Obstetrics and Gynecology (ACOG), the American Academy of 
Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) all endorse 
Gardasil 9 (Human Papillomavirus 9- valent Vaccine Recombinant) as a safe and 
effective early cancer preventing intervention immunization for adolescents. Despite 
emerging findings supporting this vaccination as cancer preventing and the endorsement 
to vaccinate early there is still parental hesitancy to immunize youth in the United States. 
Parents have vocalized concerns that providing their child with this vaccine will likely 
increase promiscuity and premature sexual activity (Boyce & Holmes, 2013). This has 
created a focus on the vaccine as one which protects against sexually transmitted disease 
and not cancer. Shifting the focus of the vaccine to the priority objective of cancer 
prevention, is an important step in advocating and promoting the purpose of the vaccine.  
Healthy People 2020 is a federally sponsored program that aims to improve 
population health across the United States (ODPP, 2017). Each decade, health objectives 
are set to help achieve their mission, often focusing on currently identified health care 
disparities (ODPP, 2017). Healthy People has been creating scientifically based goals and 
objectives for the medical community to strive towards for the last three decades (ODPP, 
2017). Various stakeholders within the health care community and the national 
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government help to draft the benchmarks for the decade (ODPP, 2017). HPV 
immunization was one measure that was identified as a health target in 2010, landing it 
on the Healthy People 2020 goals (ODPP, 2017). 
Problem Statement 
According to the Indiana State Department of Health’s (ISDH) first annual School 
Coverage Assessment Data report for 2014-2015, only 9.2% of Indiana’s sixth graders 
have had HPV immunization that matches the Advisory Committee on Immunization 
Practices (ACIP) guidelines (ISDH, n.d.). This likely would reflect partial immunization; 
however, the data could also reflect completed immunization. The data does not go into 
further description and fails to even list HPV on the county report for the same reporting 
year, likely due to such a low percentage of individuals complying with current ACIP 
recommendations. Records reflecting the percentage of sixth graders within the county 
where the project took place is not available, though a request has been sent to the state. 
Indiana is one of seven states with immunization rates of less than 49% for HPV (CDC, 
2018b). Comparatively, most of the United States has immunization rates between 50-
69%, with only another seven states achieving immunization rates above 70% and more 
closely aligned with Healthy People 2020 goals (CDC, 2018b).                                                                    
Nursing practice is well-known for its holistic approach to patient care (The 
Importance of Holistic Nursing Care: How to Completely Care for Your Patients, 2019). 
Addressing a controversial immunization such as Gardasil 9 requires the Doctoral of 
Nursing Practice (DNP) student to incorporate a holistic approach to addressing a 
practice problem while placing the patient at the center of focus. Understanding how to 
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merge information about a sexually transmitted disease that has oncogenic properties 
with a focus on cancer prevention is ideal in achieving improved immunization rates, that 
will improve population health and reduce wasteful health spending (Bigman, Capella, & 
Hornick, 2010).  
Purpose 
HPV immunization is not required for school admission in many states and 
therefore parents commonly resist this immunization (Barrazza, Weidenaar, Campous-
Outcalt, & Yang, (2016). Another influential factor that affects immunization against 
HPV is providers using mixed approaches when discussing the importance of this 
immunization with parents (Holman et al., 2014). Two commonly used approaches when 
discussing HPV immunization include a presumptive and a conversational approach, both 
of which have positive and negative implications in vaccination receptivity, which will 
later be explored in this paper. Previous researchers (Perkins & Clark, 2013) have 
suggested that provider recommendations are weak due to perception and or anticipation 
of parental refusal for this immunization, further complicating the problem and creating a 
gap in practice. The opposition and hesitancy to provide this immunization routinely has 
resulted in inadequate immunization rates and continues to leave youth vulnerable to 
common cancers secondary to persistent HPV infection(s) not cleared by the body. It also 
allows for excess expenditure related to high health cost associated with cancer treatment 
and surveillance.  
Since provider recommendations’ have been cited as a key determinate in HPV 
immunization (Fontenot, Kornides, & McRee, 2018), teaching providers how to 
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recommend this immunization to parents may be fundamental in increasing immunization 
rates to target goals. Because a parent’s decision to vaccinate or not vaccinate may be 
influenced by a provider, the provider must first understand the benefits of the 
immunization, the associated risk profile, and feel comfortable communicating and 
discussing this information and, ultimately, make a strong recommendation for the 
vaccine.  
Addressing the Gap in Practice 
To address the current gap in literature and practice, a teaching project was 
proposed to help increase provider knowledge on how to recommend and discuss this 
immunization with parents and potentially increase immunization rates. “Health care 
providers’ recommendations have been proven to be a key determinate of vaccination 
uptake [i.e., immunization uptake]” (Fontenot et al., 2018, p. 386), encouraging parental 
movement towards or against action.  The AAP (2017) and the CDC (2018d), both note 
that a strong provider recommendation is pivotal in recommending HPV immunization.  
The practiced-focused question guiding this project was Does an education 
program using concepts from the health belief model (HBM) increase provider 
perception of preparedness on how to recommend Gardasil 9 immunization in 
adolescents?  
This educational intervention may increase immunization against HPV by up to 
23% (Fontenote et al., 2018). Despite Gardasil 9 being strongly endorsed and part of the 
recommended immunization schedule, providers are falling short in making a strong and 
consistent recommendation for immunization in younger patients (Fontenot et al., 2018). 
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Decreasing the gap in literature and practice through educating providers on effective 
strategies of recommending an immunization such as Gardasil 9 is imperative to the 
promotion of population health.  
Nature of Doctoral Project 
The completed project was a staff education project that focused on educating 
providers on having effective conversations with parents about HPV vaccination. The 
target sample included primary care providers working in outpatient hospital associated 
clinics. The affiliated pediatric practices and gynecological practices were also offered 
the opportunity to participate in the educational opportunity. Those in attendance were 
clinicians from each of the practice areas identified above except for pediatrics and 
gynecology. The healthcare system is an independently owned hospital in Indiana. While 
the hospital is geographically located centrally, many of the communities it serves fall 
into rural healthcare areas. Many of the outpatient clinics are located on campus, however 
there are several providers who also travel to the hospital for administrative and 
educational task. The project occurred at the healthcare system’s main campus. All 
attendees were invited through the hospital’s email server. 
A comprehensive literature review was conducted through Walden University’s 
library database using predominantly CINHAL and MEDLINE from 2016-2019. Best 
practice guidelines for evidence appraisal were applied to all searched results. Among the 
data yielded how the recommendation is made matters. A presumptive recommendation 
also known as an announcement method in existing literature (AAP, 2017) is the 
strongest supported approach to recommending HPV immunization. 
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The guiding framework for this education project focused on increasing HPV 
immunization is the HBM. The HBM constructs will support the standardized approach 
(same day, same way approach coined by the CDC (2018dc) to recommending HPV 
immunization. Evaluating the impact of this teaching project is feasible within this setting 
through application of the standardized post education assessment questionnaire used 
within the institution’s healthcare system.  
Current vaccination rates for HPV in the clinics reflect rates of 14%, far less than 
current targets of 80% and consistent with the findings of Healthy People 2020. 
Successful application of the information presented in this educational program may 
ideally increase vaccination rates and promote a change in current practice throughout the 
organization and in other primary care and pediatric practice settings. 
Significance 
Stakeholders 
Immunization guidelines as set by ACIP (2018) and the CDC (2018c) 
recommends HPV vaccination to be administered to adolescents, both boys and girls, 
between 11 and 12 years of age. However, high-risk candidates can receive the 
immunization series starting at 9 years of age (CDC, 2018c). Existing research has even 
suggested that when the immunization series is started before the age of 15, two 
immunizations provide a higher immune response than three provided after age 15 
(Khurana, Montague, & Wiesmann, 2016). This is due to an enhanced immune response 
promoting better efficacy and immunity against HPV infections (Khurana et al, 2016). 
This finding ultimately changed the labeling of Gardasil 9 in 2017 (Khurana et al., 2016). 
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Additional organizations that support HPV immunizations per CDC and ACIP guidelines 
includes ACOG, AAFP, AAP, and American Society of Clinical Oncology (ASCO). This 
is not an all-inclusive list but reflects that stakeholders across the patient’s lifespan and of 
different practice areas support this immunization and believe in its ability to improve 
population health through cancer prevention. 
Contribution to Nursing Practice 
This teaching project lays the groundwork for future research that seeks to 
increase provider knowledge of making a firm recommendation for Gardasil 9 and its 
cancer preventing benefits. Since vaccination receptivity is less than desired and the 
problem stems not just from parental opposition, but poor and inconsistent provider 
recommendation (Haelle, 2015), by equipping providers on how to have better 
conversations with parents about HPV, immunization rates are expected to increase. Due 
to some of the challenges within the current health care infrastructure, it may take a series 
of actions to improve the HPV vaccine immunization process and ultimately raise rates to 
those held by Healthy People 2020. With my project, I sought to strengthen the current 
process through standardizing the approach by using a presumptive method and teaching 
providers how to have a conversation with parents about a current controversial vaccine. 
With vaccines for other sexually transmitted diseases currently being studied, health 
providers need to understand how to encourage patients to be stewards of their own 
wellness journey. 
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Generalizability 
Upon completion, the provider educational initiative has the potential to be 
delivered to providers in other facilities. Targeting HPV immunization rates aligns with 
all required criteria for DNP attainment at Walden University. This simplified process 
will improve the current standard of practice as supported in existing research and ideally 
will encourage other primary care practitioners to institute the recommendation into 
practice to help improve the health of their patients. In addition to influencing current 
practice change, this project can be applied to other areas of practice, improving health 
care systems on a larger scale. The practice change is not only supported in literature, but 
is affordable, efficient, and delivers the right care to the right individual, at the right time. 
Implementing the proposed change may enhance workflows while simultaneously 
improving population health.  
Implications for Social Change  
Understanding how to discuss tabooed topics is essential to health and wellness. 
HPV immunization is a prime example of how providers have uncertainty discussing 
topics that are viewed as uncomfortable but are still very much important to overall 
health. Learning how to discuss a sexually transmitted viral infection that causes cancer 
and its antidote with parents is a novel approach to learning how to discuss other health 
related behaviors and topics with our patients and has numerous benefits, such as 
enhancing patient provider relations and encouraging shared decision making with the 
patient. If health care providers can communicate the importance of receiving HPV 
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immunization, more adolescents may get immunized and thereby reducing the likelihood 
of developing HPV-related cancers.  
Summary 
Tackling cancer rates through educating providers on how to make a 
recommendation for a particular immunization seems like it would be an outdated idea 
during a time when most individuals know someone with cancer or have lost a loved one 
to cancer. Unfortunately, when the cancer can result from a persistent viral infection 
obtained years before its oncogenic manifestations this is not the case. Of three vaccines 
originally marketed for cancer prevention; Gardasil 9 is the only immunization available 
that can prevent cancer caused from the HPV virus (Brookes, 2016). Sadly, when parents 
fear giving their child this immunization and providers are poorly equipped in discussing 
this vaccine it leaves youth vulnerable to preventable cancers.  
I sought to help bridge the gap that exists between literature and practice and to 
help guide providers in having successful discussions with parents about protecting their 
child’s health. In Section 2, the background and context of Gardasil 9 will be further 
explored. Additionally, incorporating the HBM into the educational activity will 
ultimately help increase immunization rates. The role of the DNP student and my interest 
in topic will be outlined within the context of the project. 
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Section 2: Background and Context 
Introduction 
Literature reflects that presentation is key to parental receptivity of immunization 
with this more controversial vaccine. In a literature review on HPV, 10 of 11 studies 
analyzed reflected a mean average of 34.7% immunization completion (Bartlett & 
Peterson, 2011). Healthy People 2020 supported this data in their current report on 
immunization rates for HPV. These rates are far below the target goal of 80% (AAP, 
2017). Educating providers on how to have conversations about HPV immunization 
effectively is crucial in bridging the gap that exists between current practice and ideal 
outcomes (Perkins, 2013). This section will explore specific health behavior theories, the 
relevance of this project to nursing, the local background and context and the role of the 
DNP student, and the project team. 
The consistent demonstration of Gardasil 9 as an effective means of cancer 
prevention has prompted the recommendation that HPV vaccination should be given at 
every clinical opportunity (Reagan-Steiner et al., 2015), based on current 
recommendations. While scientists are still working on better understanding the most 
efficacious ways of promoting vaccine acceptance among vaccine-hesitant parents (Opel 
et al., 2015), many sources exploring HPV vaccine resistance and uptake in parents have 
linked a strong provider recommendation with increased acceptance. Clark, Cowan, 
Filipp, Fisher, and Stokley (2016) reported the physician recommendations as critical, 
others note it as “the most important determinant” (Perkins & Clark, 2013, p. 828). 
Through a presumptive recommendation, it is believed that the strong provider 
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recommendation will reflect as pivotal in increasing HPV vaccination rates (Holman et 
al., 2014).  
While many studies have assessed and analyzed the importance of communication 
on parental acceptance of HPV, there is still resistance among the health care community 
to adhere to best practice recommendations when offering HPV vaccination. While there 
is little existing research on the continued resistance towards Gardasil 9 immunization, 
some existing research suggests that providers are uncomfortable to initiate the 
discussion for fear of parental disagreement (see Haelle, 2015).  
Current literature, however, reflects that a presumptive recommendation is the 
most successful, as it does not isolate the vaccine and prompt parental hesitance (Gilkey 
et al., 2016). When the provider recommends and provides education about the 
vaccination in a similar fashion as other important immunizations required in adolescents, 
it decreases the isolation and stigma associated with HPV immunization. According to 
Opel et al. (2015), “There is concern that providers’ use of presumptive formats to initiate 
vaccine discussions, despite precipitating less verbal resistance from parents during visits, 
“may negatively affect parents’ experiences” and “result in decreased vaccine uptake 
over time” (Opel et al., 2015, p. 1998). However, emerging information from research in 
practice, suggest that conversational approaches (involving extensive dialogue between 
the provider and patient) towards Gardasil 9 are inferior compared to announcing 
immunization (Brewer et al., 2016). Low immunization rates, both initiated and 
completed, are supported in current data for Gardasil 9 series, reflecting rates far less than 
target goals of 80% (AAP, 2017). How the vaccine is presented and recommended 
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matters. While some believe a concise approach is best, others find it may cause distrust; 
though all agree a strong recommendation promotes vaccination.  
Concepts, Models, and Theories 
Many concepts have been explored in seeking to understand the current 
opposition to HPV immunization. Concepts documented throughout existing literature 
include parental hesitance, a weak provider recommendation, and poor understanding of 
risks and benefits of immunization (Gilkey et al., 2016). These concepts are common 
themes when researching HPV immunization. Even Merck, who manufacturers Gardasil 
9, supports a strong recommendation from clinicians to effectively promote 
immunization (Merck, 2016). Understanding how to make a presumptive 
recommendation with a concise approach and focus on cancer prevention is key when 
responding to parents and adolescents who have questions or wish to pursue additional 
dialogue. 
Theoretical Concepts and Models 
Models such as the HBM are also prevalent and frequently referenced within the 
literature. The HBM focuses on six constructs that influence a patient’s decision to elect 
or opt out of a treatment plan (Glanz, Rimer, & Viswanath, 2016). The six constructs 
include (a) perceived susceptibility, (b) perceived severity, (c) perceived benefits, (d) 
perceived barriers, (e) cues to action, and (f) self- efficacy (Glanz et al., 2016). Each of 
these constructs is influenced by modifying factors which explore the constructs before 
resulting in an independent action (Glanz et al., 2016). This information was adapted with 
permission and is reflected in Table 1. 
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Table 1 
Health Belief Model Applied to Immunization 
 
 
 
    
Note. Adapted from “Making sense of perceptions of risk of diseases and vaccinations: a 
 qualitative study combining models of health beliefs, decision-making and risk 
 perception,” by Bond, and Nolan, 2019, BMC Public Health, 11. Open Access. 
 
Concept Definition Application 
   
Perceived susceptibility 
 
Concern for odds of contracting 
HPV over one’s lifetime 
 
Define population risk, lifetime 
prevalence. 
 
Align risk with individual patient. 
   
   
Perceived severity 
Concern for how threatening 
HPV infections are or how great 
the risk of complication is. 
Define infection (acute and 
persistent). 
 
Discuss complications of disease 
infection. 
 
Review mortality. 
   
Perceived benefits 
Assessed value of immunization 
in regard to decreasing chance 
of developing HPV infection or 
complications 
Discuss immunization guidelines 
and recommendations. 
 
Review importance of research 
supporting recommendations. 
   
Perceived barriers 
Concern for complications post 
immunization. 
Discuss parental concerns. 
 
Discuss provider concerns. 
   
Cues to action Engaging readiness to act 
Educate providers on discussing 
HPV immunization with parents. 
 
Introduce CASE acronym. 
 
Share evidence-based practice 
that has increased immunization 
rates. 
   
Self-efficacy 
Viewing oneself as able to 
attain desired health through 
action. 
Increase overall knowledge. 
 
Reduce anxiety about 
immunization. 
 
Equip with told for successful 
implementation. 
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My goal with this project was to increase HPV vaccination rates to their 
recommended levels of 80% through educating staff on the HBM constructs and 
incorporating a new process of making a presumptive recommendation to increase 
current vaccination rates thus, improving the overall healthcare of the adolescent and 
young adult population of the community. This simplified process may improve the 
current standard of practice as supported in existing research and may encourage other 
primary care practitioners to institute the recommendation into practice to help improve 
the health of their patients. In addition to influencing other practitioners to change their 
current approach, this project can be applied to other areas of practice, improving health 
care systems on a larger scale. 
Arguably, the six constructs could be incorporated to more elaborate 
conversations about the HPV immunization, though they may be addressed in a concise 
approach coined by Merck. Merck (2016), the manufacturer of Gardasil 9, proposed that 
providers use the CASE acronym, when discussing Gardasil 9 with parents. The CASE 
acronym stands for Cancer Prevention, Adolescent Immunization, Safety Profile, and 
Exposure (Merck, 2016). The CASE acronym correlates with the six constructs of the 
HBM. The AAP and CDC also have tools available for providers to use when discussing 
HPV immunization with parents; many of their tools focus on the vaccine preventing 
cancer, giving the immunization between 11 and 12 years of age, and the immunization 
being safe and effective. Because of the AAP (2017) and CDC’s (2018d) position that a 
strong provider recommendation is pivotal in recommending HPV immunization 
elaborate discussions, also known as a conversational approach, have been suggested to 
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negatively influence immunization and therefore a more concise approach is strongly 
promoted throughout literature (Brewer et al., 2017). Making a presumptive 
recommendation implies that the parent will elect to immunize their child against 
whatever disease(s) is indicated for their age (Brewer et al., 2017). The HBM constructs 
encourage concise and effective discussions regarding HPV immunization. Since how the 
vaccine is recommended matters; using a standardized approach that emphasizes the 
importance of 9vHPV in an informative, yet concise, and nonbiased approach is key.  
The HBM, although originally created as a psychological theory, is applicable in 
nursing practice as it helps to explore and explain health behaviors (Health Belief Model, 
2012). Despite the current literature available on HPV immunization uptake, there is still 
much to be learned by applying the HBM to current practice. The psychological 
constructs of the HBM help nursing scientist to understand the driving external forces 
which promote preventative health measures and ensure enhanced practice outcomes 
(Turner, Hunt, DiBreezo, & Jones, n.d). 
Since the HBM explores influential factors related to health promotion behaviors, 
understanding current parental and provider knowledge of persistent HPV infection is 
key to education initiatives in the future. Making a presumptive recommendation for 
vaccination however, assumes that the benefit is greater than the risk and proactively 
increases population health. Despite a presumptive recommendation being used, parents 
may elect to further discuss HPV immunization with the provider before their child 
receives the vaccine thus, allowing the opportunity to focus more on the constructs of the 
HBM in practice application. This is also a time to acknowledge parental concerns and 
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reinforce benefits of HPV immunization. The CDC (2018d) has drafted an educational 
tool for providers (available online) suggesting how to respond to parental concerns 
regarding HPV immunization. The concepts reflect concise responses that reinforce the 
constructs relative to the HBM (CDC, 2018d). Many of the HBM constructs are aligned 
to talking points outlined by the CDC in Table 1. The AAP (2019) also has materials 
available through the HPV Champion Toolkit targeted at parents that speak to many of 
the constructs within the HBM. The American Cancer Society (2017) has also produced 
an infographic focused on concise yet important reasons for HPV immunization to be 
given between 11 and 12 years of age. 
Modifying factors of the HBM related to HPV immunization include the parent, 
the youth, age, education, awareness of risk and consequences, accessibility, 
affordability, and the provider’s delivery of the recommendation (Opel et al., 2013). 
Various clinicians have sought to better understand the influence of the modifying factors 
through qualitative research (Bigman, et al., 2010; Eby, 2017; Mehta, Sharma, & Lee, 
2013). To date, the medical community still does not clearly understand all the modifying 
factors and their relationships to HPV immunization (Grabiel et al., 2013). Incorporating 
the HBM constructs into the recommendation for HPV immunization is thought to be 
essential to increasing immunization rates of both male and female adolescents (Eby, 
2017; Mehta et al., 2014). Applying the HBM as a theoretical underpinning while making 
a presumptive recommendation is only going to be reflected after years of application. 
One recurring theme throughout literature reviewed is that how the recommendation is 
made matters (Liddon, Michael, Dittus, & Markowitz, 2013; Opel et al., 2013;). 
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Presumptive recommendations have worked well in other disease states, but has been 
ineffective in HPV (Gilkey et al., 2016). A presumptive recommendation assumes that 
the parent is willing to proceed with following the standard immunization schedule, 
whereas a participatory recommendation allows the parent to decide which 
immunizations the child will or will not be receiving during the encounter (Opel et al., 
2013). Bigman et al., (2010) note attribute framing, in health communication, is a concept 
explored by Kahneman and Tversky suggesting that “people make inferences based on 
the context in which choices are presented”. One reason HPV immunization is less than 
ideal in part may be due to the lack of understanding of how best to make the 
recommendation.  While some researchers have looked at demographics, others have 
looked at the crafting of the message to explain immunization rates.  Possibly the missing 
link is crafting the message effectively to all demographic populations.   
Evaluating existing literature and grading it for scientific rigor with a level of 
evidence appraisal system is important to controlling bias and supporting a nonbiased 
recommendation for HPV immunization in adolescents. The pyramid of nursing research 
hierarchy was used to appraise the existing literature resulting from the data base 
searches. The evidence-based medicine pyramid/ the pyramid of nursing research 
hierarchy is depicted in Figure 1. 
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Figure 1. Depiction of evidence appraisal system. Adopted for use from Walden 
University “Evidence-Based Practice Research: Levels of Evidence Pyramid” Produced 
by Jan Glover, David Izzo, Karen Odato, and Lei Wang. Copyright 2006, by Trustees of 
Darmouth College and Yale University. Adopted with permission. 
 
Definition of Key Terms 
Adolescent: An individual 11-17 years of age (Cates, Ortiz, Shafer, Romocki, & 
Coyne-Beasley, 2012). 
Clinicians: All clinical staff: physician, physician assistant, nurse practitioner, 
medical student, nurse practitioner student, physician assistant student, nurse, medical 
assistant, or nursing/ medical assistant students within the clinical setting (Bigman, et al., 
2010).  
Cost burden: Total sum of all education, screening, and treatment of a disease 
state (CDC, 2013a). 
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High risk for HPV: Immunocompromised state, including HIV and those who 
have been sexually abused or assaulted (CDC, 2018c). 
HPV immunization: Cervarix, Gardasil, or Gardasil 9 vaccine (Dekker, 2006).  
HPV infection: Having any HPV strain diagnosed or undiagnosed by standard 
screenings (Shanmugasundaram & You, 2017). 
Immunization Uptake: Receipt of the recommended immunization (Griffioen, et 
al. 2012). 
Inadequate immunization rates: Immunization rates less than 80% for target 
population (ODPP, 2017). 
Mandate: State-governed enforcement of a recommendation, typically enforced 
with school or daycare admission (AAP, 2017). 
Medical community: Hospital systems, networks, inpatient and outpatient clinics, 
and staff members (Eby, 2017). 
Parent: The responsible party involved in medical decision of patient. (Edwards, 
Hackell, 2016). 
Patient: Any individual presenting for medical care or authorized to make 
medical decisions on the behalf of the recipient receiving medical care (Ziarnowski, 
Brewer, & Weber, 2009).  
Persistent HPV infection: Any infection from an HPV strain that is not cleared 
from the body in 6 months (Shanmugasundaram & You, 2017). May or may not be an 
incidental finding on abnormal pap smear results (Shanmugasundaram & You, 2017). 
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Practitioners: Any licensed physician, physician assistant, or nurse practitioner 
(Bigman, et al., 2010) 
Presumptive recommendation: The assumption that current recommendations and 
standard of care are desired by the patient seeking medical care (Brewer et al., 2017). 
Provider: Any physician, physician’s assistant, nurse practitioner, medical 
student, nurse practitioner student, or physician assistant student (Bigman et al., 2010). 
Sexual activity: Any contact that occurs between two individuals with the purpose 
of sexual arousal- including but not limited to penetration and oral sex (Mortensen, 
Adam, & Idtaleb, 2015). 
Youth: Inclusion of any child 9 to 17 years of age (Meites, Kempe, & Markowitz, 
2016). 
Relevance to Nursing Practice 
Cervical cancer deaths may be reduced by as much as two thirds with 
immunization rates of 80% (Boyce & Holmes, 2013). “The Journal of Infectious Diseases 
reveals that since the vaccine was introduced in 2006, vaccine-type HPV prevalence 
decreased 56 percent among female teenagers 14-19 years of age” (CDC, 2013b, para. 1). 
Likewise, vaccination rates above 95% ensure herd immunity (Zangger Eby, 2017), a 
necessity of public health maintenance. Public health dollars and medical spending can 
significantly be reduced through increasing vaccination uptake of HPV. Ninety percent of 
genital warts are caused by two common strains, in which HPV vaccination offers 
protection against (Bigman et al., 2010). HPV is associated with nearly 100% of all 
cervical cancers and their precursors worldwide (Arrossi et al., 2017) and could be 
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dramatically reduced with adoption of recommended immunization practices. Seventy 
percent of the cervical cancers originate from HPV infection with strains 16 and 18 
(Grabiel et al., 2013). HPV associated oropharyngeal cancers average almost 9,000 
annually, with a majority of these cancers also being preventable with 4vHPV and 
9vHPV (Kram, Schmidt, Saghezchi, & Russell, 2015).  
Conducting scientific research and analysis, such as the educational intervention, 
helps to identify the risks and benefits of the current recommendations and helps drive 
understanding of both immunology concepts and health promotion (National Academy of 
Sciences, National Academy of Engineering, and Institute of Medicine (US) panel on 
International Benchmarking of US Immunology Research, 1999). The National Cancer 
Institute a subsidiary of the National Institute of Health (NIH), has published the 
following claims: “In the trials that led to the approval of Gardasil and Cervarix, these 
vaccines were found to provide nearly 100% protection against persistent cervical 
infections with HPV types 16 and 18 and the cervical cell changes that these persistent 
infections can cause. The trials that led to approval of Gardasil 9 found it be nearly 100% 
effective in preventing cervical, vulvar, and vaginal disease caused by the five additional 
HPV types (31, 33, 45, 52, and 58) that it targets.” (National Cancer Institute, 2018, para. 
10). 
The National Cancer Institute further notes that a phenomenon such as cross-
protection was observed with clinical trials of Cervarix, which is no longer available in 
the United States due to inferiority when compared to 4vHPV and 9vHPV (Mulcahly, 
2016). The National Cancer Institute found that during a 4- year period in Australia, 
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genital warts decreased in both males and females, when high immunization rates were 
provided to females only (2018). While ongoing research is helping us to further 
understand how long protection is offered from the immunization, researchers believe it 
to have lasting effects for nearly a decade (Markowitz, 2018).  
Practice Problem 
Since the debut of Cervarix and recommendations for routine immunization, there 
has been opposition to the vaccine from parents and clinicians alike (Haelle, 2015). The 
opposition and hesitancy to provide this immunization routinely has resulted in inferior 
immunization rates and continues to leave youth vulnerable to common cancers 
secondary to persistent HPV infection(s) not cleared by the body (Cates et al., 2012). 
Low HPV initiation and completion rates are multi factorial in origin as noted by 
Grabiel et al., (2013). Existing nursing and medical literature suggest poor HPV 
vaccination uptake rates can be attributed to weak provider recommendation, 
misconceptions of perception and receptivity about HPV vaccination between parents and 
clinicians during appointments, and knowledge deficits of parents and providers alike 
(Katz et al, 2016, Liddon et al., 2013). Merck has strongly supported advertising 4vHPV 
and 9vHPV as cancer preventing immunizations to help refocus parents and providers 
concerns regarding HPV immunization. Cervarix was also promoted as a cancer 
preventing immunization while in the U.S. market (Mulcahy, 2016). Cervarix offers 
protection against HPV types 16 and 18, both of which have oncogenic propensity 
(Cervarix Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, ASO4 
adjuvanted) Consumer Medicine Information, n.d). Merck pushed the cancer prevention 
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ideology following realization that despite three available vaccines on the market for 
cancer prevention, there was still resistance to the immunization due to negative 
perceptions about the sexual transmission of HPV and youth. Since vaccination is most 
effective before sexual debut, promoting vaccination effectively is key to cancer 
prevention (Lockwood-Rayermann & McIntyre, 2009). The American Society of Clinical 
Oncology (ASCO) recommends HPV immunization as well (Mulcahy, 2016). Most of 
the literature emphasizes that presentation is key to parental receptivity of immunization 
with this more controversial vaccine (Liddon et al., 2013, Kester et al, 2013, and 
Todorova, Alexandrova-Karamanova, Panayotova, Dimitrova, & Kotzeva, 2014).  
The delayed implementation reflects a clear need for an educational project that 
starts at the foundation of the problem; educating providers on how to have reproducible 
and effective conversations with parents. The emerging evidence and findings will 
contribute to the nursing profession and guide nurse practitioners and other providers to 
implement similar improvement initiatives in their practice settings to address similar 
concerns. 
Practice Recommendations 
As the health care system strives to reduce disease burden and cost across the 
nation, improvement on preventative health is essential (Institute of Medicine, 2010). 
Providers and other health care professionals need to work together to find approaches 
based in science; that enhance patient care delivery systems and yield desired outcomes. 
Delayed translation of evidence into practice is a well-known concern throughout 
research driven clinical practice, with delays averaging 17 years (Morris, Wooding, and 
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Grant, 2011). Our nation’s health cannot afford further delays in care improvement. 
Innovative and evidence-based practices need to be implemented efficiently and 
effectively, with cost containment considerations. 
Targeting HPV immunization rates aligns with Healthy People 2020 goals; 
because of the related disease burden with chronic HPV infection and oncogenesis, 
objectives were drafted addressing HPV transmission through promotion of HPV 
vaccination (Kester, Shedd-Steele, Dotson-Roberts, Smith, & Zimet, 2014). However, 
since it has been highly controversial since its debut, there has been much resistance from 
vaccine-hesitant parents as a result of negative media attention, religious resistance, and 
provider hesitance (Griffioen et al., 2012). It is time to address the issues hindering 
uptake and modify current practice.  
Immunization guidelines as set by The CDC and the ACIP recommends HPV 
vaccination to be administered to adolescents, both boys and girls, between 11 and 12 
years of age. However, high-risk candidates can receive the immunization series starting 
at 9 years of age (CDC, 2018c). Late in 2018, the CDC made the recommendation to 
extend Gardasil 9 immunization in men and women 26-45 years of age (Markowitz, 
2018). This recommendation came from information in Merck’s phase three trial 
pertaining to Gardasil 9; the study supports immune response for at least 10 years after 
the vaccination is given (Advisory Council on Immunization Practices [ACIP], 2018). 
Extending this recommendation to older women and men helps to address the second 
peak in HPV infection that is commonly seen between 35 and 55 years of age in women 
(Harper and Vierthaler, 2011). Given the momentum in healthcare to incorporate 
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evidence-based research into practice, making a strong recommendation in a timely 
fashion addresses the current gap in practice. 
Strategies for bridging the gap. Many theorists have developed grand theories 
placing the patient at the center of nursing care; these scientists have contributed to 
nursing through analysis and synthesis of information obtained in the field of nursing 
(Hoeck & Delmar, 2017). They have collected information from practice and 
observation, and they have laid the groundwork for future nursing researchers (Hoeck & 
Delmar, 2017). This project aligns with that premise. As a DNP trained nurse, a project 
that focuses on understanding what drives and influences population health further 
contributes to the holistic model upon which nursing practice is based. This teaching 
project will apply concepts found in research to address deficient and practice gaps that 
seek to improve population health. Closing the gap between evidence and practice, by 
addressing inefficient approaches to increasing HPV immunization through enhanced 
educational awareness. Although the project occurred in an urban area, its potential to 
influence nursing practice can be seen at the state and even national levels. 
Nurses are known for their holistic approach to healthcare, differentiating us from 
other clinicians. While many studies have assessed and analyzed the importance of 
communication on parental acceptance of HPV, there still is resistance among the 
medical community to adhere to best practice recommendations when offering HPV 
vaccination (Warner et al., 2017). The delayed uptake in implementation of effective and 
concise conversations with parents about HPV immunization, reflects a clear need for a 
teaching project that is reproducible and effective. Initiating an educational project that 
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educated providers on how to engage parents in dialogue about Gardasil 9 that is 
measured with a simple standardized questionnaire seeks to improve immunization rates. 
The emerging evidence and findings can contribute to the nursing profession and guide 
nurses to implement similar teaching initiatives in their practice settings to address 
similar concerns. 
According to the American Association of Colleges of Nursing (AACN), a DNP 
prepared nurse will focus their studies on a practice focused research application as part 
of the requirements to obtain a terminal degree (AACN, 2006). Doctoral prepared nurses 
must reflect leadership in practice through scientific inquiry and practice (AACN, 2006). 
Evidence based guidelines can be translated and synthesized into clinical practice when 
concepts, models, and theories guide practice-based research (AACN, 2006). Findings 
from practice-based research versus philosophical research shape nursing as a profession, 
contributing to the existing scientific body (AACN, 2006). Nursing scientist reflect their 
professional dedication to improved care through researching and evaluating current 
approaches to care delivery systems (AACN, 2006). 
Local Background and Context 
The United State Census Bureau reports that there are just under 6.7 million 
residents in Indiana, with 23% of the population being identified as youth (2017). Indiana 
is one of seven outlying states that has inadequate immunization rates against HPV 
(CDC, 2018b). Indiana’s youth is far below target goals for HPV immunization, with 
under 10% of adolescents having received HPV immunization (IDSH, n.d.). 
 Persistent HPV infection has been linked with cervical, vaginal, vulvar, penile, 
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rectal, and oropharyngeal cancers in both men and women (AAP, 2017). HPV infection is 
also responsible for the majority of genital warts (Todd, 2017). Many have postulated 
that parental and religious opposition to the immunization is centralized around its 
benefits of providing protection against sexually transmitted infections, such as genital 
warts (Kester et al., 2012). Coupled with parental concerns that providing their child with 
this vaccine will likely increase promiscuity and premature sexual activity (Boyce and 
Holmes, 2013) has enhanced the focus on the vaccine as one which protects against 
sexually transmitted disease and not cancer. Hence, shifting the focus of the vaccine on 
cancer prevention is key. 
Institutional Context 
The doctoral project took place in an urban healthcare system in Indiana. The 
outpatient primary care clinics are comprised of predominantly physicians and nurse 
practitioners, with 23 providers in total. There are approximately 50,000 patients included 
in the practices’ patient panels. Demographically, about 3,000 of these patients are youth, 
between 9-14 years of age. All providers were invited to the monthly lunch in-service, 
known as the round table. The providers who attended were educated on how to facilitate 
a strong recommendation for HPV immunization rooted in application of the health belief 
model. Provider’s knowledge of the content of the educational program, on how to 
approach the discussion with parents utilizing an evidence-based approach, was evaluated 
for enhanced content knowledge and comfort with a questionnaire following the in-
service. The questionnaire is a standardized evaluation tool used within the healthcare 
system for all teaching events. 
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In addition, increasing HPV vaccination in the primary care setting addresses one 
of the Health Effectiveness Data Information Sets (HEDIS) measures, which not only 
promotes improved healthcare through attainment of quality metrics, but also influences 
reimbursement (National Committee for Quality Assurance [NCQA], 2018). This is 
beneficial because the health care system is transitioning to a pay for performance model 
where high-quality care is reimbursed and substandard care is penalized. Furthermore, 
the healthcare network is one of the few independently owned hospitals in the area. 
Therefore, lost revenue due to low immunization rates (i.e. substandard care) has the 
potential to significantly influence the economical fate of the hospital when paired with 
other penalties. Lastly, the teaching project not only met the DNP Walden University 
Education Manual criteria, it also aligns with DNP essentials as set forth by the AACN, 
and standards of practice set forth by the American Nurses Association (ANA).  
Federal Context 
The cost burden of HPV infection is thought to be second highest to that of 
human immunodeficiency virus (HIV) (CDC, 2013a). Cost is tabulated after taking into 
consideration the cost of preventative screenings, treatment of abnormal pap smears, 
repeat testing for surveillance monitoring; in addition, costs affiliated with treatment of 
genital warts and cancer related treatments. In 2015, a study estimated the direct medical 
cost of preventing and treating HPV infections to be eight billion dollars (Chesson, 
Donatus, Mona, Meg, & Douglas, 2012).  
During a time when the US health care system is seeking to reduce cost and 
improve care outcomes, focusing on prevention is essential to achieving these goals. 
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Promoting HPV immunization at target rates, can reduce the cost burden on the health 
care system while improving the overall population health of todays’ youth. With 
Gardasil 9 being a recommended adolescent immunization, coverage and access to the 
immunization is enhanced. Sadly, the lack of state mandate also influences series 
initiation and completion rates. 
Educating providers on having appropriate conversations about Gardasil 9 helps 
to explore the relationships between current immunization practices and guidelines. The 
teaching project evaluated teaching objectives that focused on enhanced knowledge 
content about recommendations for Gardasil 9. These findings contribute to the current 
body of literature that seeks to understand the relationships that exist between the two. 
Sub sequentially, the end goal of the project was to increase HPV immunization rates to 
the target goal of 80%; similar to that of Tdap and Meningococcal rates currently 
(NCQA, 2018). Knowledge gained from the educational intervention has potential to be 
applied in various practice settings where immunizations are provided, thus increasing 
immunization rates to target goals outside of primary care. 
Role of the DNP Student 
Professional Context 
As the DNP student I was the project manager and responsible for designing, 
implementing, and reviewing the completed attendee evaluation forms for the proposed 
teaching project.  I analyzed the evaluations from the educational presentation. I   
launched an educational in-service that focused on evidence-based recommendations for 
practice and helped the organization to synthesize the material efficaciously.  
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I work in the primary care setting in a rural health care clinic where I provide care 
to individuals of all ages. As a mother of three, I can relate to parental concerns about 
recommendations for or against immunization. Like many of the parents and children I 
provide care to, I understand the importance of knowing that the decisions we are making 
for our children are the best decisions. I share their concerns about safety, efficacy, and 
necessity (especially as it relates to concerns about promoting promiscuity), and I treat 
my patients like family. 
Within this setting, I can also appreciate the lack of available resources and tools 
that many of the patients I care for have within their reach. While cervical cancer 
screenings are typically covered under preventative health, I provide care for many 
women who have not remained active in screening for a multitude of factors; some of 
which have had a history of abnormal pap smears from persistent HPV infections. Many 
oral cancers have also been attributed to persistent HPV infection (Markowitz, 2018) and 
there are many individuals who do not have access to routine dental care. While 
screening helps to detect abnormal findings early, a vaccination such as Gardasil 9 also 
offers an additional safety net for the future generation of men and women within the 
community (ACIP, 2018). Many of which, may neglect recommended health screenings 
for reasons outside of accessibility. Making a strong recommendation for Gardasil 9 is 
critical to ensuring health promotion for today and future generations.  
Motivation for Project 
In pursuit of attaining my DNP, I wished to explore something that I wanted to 
learn more about that would not only benefit my family, but also impact population 
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health. Immunizations seemed like a great topic to pursue advanced knowledge on, as I 
wanted to support my patients who had concerns or reservations about a particular 
vaccination, while providing a balanced perspective on risks versus benefits. Through 
applying scientific research methods to my data collection and review I was able to 
scientifically conclude that immunization against HPV is in the best interest of my 
children and the families that I provide care for.  
Biases 
Over the course of my DNP, I learned about the importance of critically 
appraising evidence to avoid implementing findings from poor quality research. I applied 
these basic concepts as I explored immunology and HPV immunization; ultimately 
influencing my previously undetermined stance on this particular immunization. Through 
continual reflection on information provided by my literature search, immunology 
education and current and historical practice experience, I am able to control my personal 
bias. Focusing on recommendations backed by the CDC and AAP also helps to reduce 
personal bias that may be associated with the potential bias of the vaccine’s value from 
the manufacturer, Merck. 
Role of the Project Team  
The project team incorporated team members within the organization interested in 
increasing HPV immunization rates. The chief medical officer (CMO) as well as the chief 
nursing officer (CNO) also served on the project team. Their roles focused on the 
educational in-service aspect to ensure the information was rooted in sound evidence 
before dissemination. The clinical quality team manager assisted in identifying current 
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HPV immunization rates within the organization as well as heading up an HPV 
immunization improvement project. Attendees also served as part of the project team as 
they provided feedback on the information presented. 
Prior to selecting the presentation time, the proposed teaching project was 
presented to the CMO. Once they approved the presentation, and with Walden’s 
institutional review board (IRB) approval (04-04-19-0397799) the educational activity was 
scheduled. Emailed invitations were sent to all clinical team members inviting them to 
the scheduled round table educational event. Attendees were provided with patient 
resources (found in Appendix C) to aid in educating parents and adolescents on HPV 
infection and immunization. Additional resource links were also included within the 
power point which served as the primary teaching tool in this educational intervention. 
How these resources are utilized within the practices will ultimately be decided on by the 
individual providers. Information for parents and providers alike focused on the cancer 
preventing benefits of Gardasil 9 immunization. 
I performed a comprehensive literature review for the purpose of better 
understanding each of the constructs of the HBM in relation to HPV immunization. 
Through enhanced knowledge of the topic, I was able to educate staff members within 
the health care facility about preferred conversational approaches on HPV immunization 
supported by the CDC, AAP, and ACS. Staff education focused on the design, safety and 
efficacy of Gardasil 9 immunization. Attendees completed an evaluation of material 
content as it related to enhanced knowledge following the in-service. 
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Summary 
Using a theoretical model such as the HBM, to support teaching points, was 
essential in enhancing provider knowledge of factors that drive medical decision making 
in patients. Through a deeper knowledge of intrinsic and extrinsic forces that lead to a 
health promotion, clinicians are able to confidently discuss HPV immunization with their 
patients. Evidence based practice synthesis and translation will promote overall 
population health, both locally and nationally. The project team ensured the information 
presented was of scientific rigor and used the educational opportunity as a means of 
promoting HPV immunization within the local organization. In section 3, the current 
literature and evidence of this topic is presented and evaluated for applicability as well as 
strong scientific underpinnings. 
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Section 3: Collection and Analysis of Evidence 
Introduction 
Health care delivery systems are changing to meet the diverse needs of patients, 
families, and communities. Health systems, like many other industries, are seeing 
numerous changes and are challenged to keep pace while enhancing outcomes. Meeting 
change with leadership and evidence-supported practice guidelines helps to ensure that 
care is personalized and more efficient than ever before (Morris et al., 2011). Addressing 
HPV immunization with a standardized process may help to ensure that all appropriate 
patients are immunized and protected in a timely fashion. The following sections will 
further explore how current evidence-based findings can be applied to practice to help 
promote enhanced outcomes in population health. 
Practice-Focused Question 
 Rates of adolescent immunization vary greatly, with nearly two-thirds of 
adolescents receiving the recommended Tdap and Meningococcal immunizations, but 
only one-fourth to one-third receiving HPV immunization as recommended (Federal 
Interagency Forum on Child and Family Statistics, 2016). Unlike young children, 
adolescents do not commonly present to the office for well adolescent checks, making it 
even more important to address immunizations at every available opportunity (Wong, 
Taylor, Wright, Opel, & Katzenellenbogen, 2013). For this reason, the CDC (2018d) 
promoted making the recommendation the same day, the same way. Promoting provider 
confidence in making the recommendation for HPV is essential to helping reduce the gap 
in practice and increase immunization rates to target levels. The practiced-focused 
38 
 
question is: Does an education program using concepts from the health belief model 
(HBM) increase provider perception of preparedness on how to recommend Gardasil 9 
immunization in adolescents?  
Aligning Practice with Purpose  
Providing youth with Gardasil 9 immunization is recommended and endorsed by 
numerous organizations. The CDC recommends providing HPV immunization between 
ages 9-14 with a two-dose series, unless the patient is immunocompromised (AAP, 
2017). The immunization schedule is drafted by the ACIP and published through the 
CDC annually (CDC, 2016). Some organizations that support the current immunization 
schedules are the AAFP, AAP, and the ACOG (CDC, 2018c).  
In the case of HPV immunization, research has strongly reflected that there is a 
poorly understood rationale for immunization uptake of Gardasil 9. Influencing factors 
that have been evaluated include knowledge of HPV infection, educational backgrounds 
of parents, exposure to complications from persistent HPV infection(s), and provider 
recommendation (Grabiel et al., 2013; Kester et al., 2013). The teaching project applied 
concepts from literature with practice validating importance of a strong presumptive 
recommendation as an influential factor in increasing Gardasil 9 uptake. 
Advanced practicing nurses are called to promote population health through 
evidence-based synthesis and translation. According to the AACN, a DNP prepared nurse 
will focus their studies on a practice focused research application as part of the 
requirements to obtain a terminal degree (AACN, 2006). Educating providers on how to 
recommend HPV immunization in accordance to evidence-based practice guidelines 
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helped to standardize recommendations and lay the foundation for increasing 
immunization rates in youth (Clark et al.,2016; Dekker, 2006; Haelle, 2015). This project 
enhanced care delivery and population outcomes through the synthesis and translation of 
current research. Reducing infections and oncogenic mutations from persistent infections 
ultimately translates to improved population health and reduced health care expenditures 
both locally and nationally thus reducing the gap in practice.  
Sources of Evidence 
Existing literature about HPV immunization was extensively reviewed as well 
outlined within the power point and was used as the main educational piece I shared with 
attendees. The power point slides (see Appendix B) were available in print the day of the 
presentation to allow for providers to take notes and refer to the material and references. 
There was also vaccine related information from Merck such as the package insert and 
current education pieces for providers to reference about the vaccination use, safety, 
efficacy, and additional information that may be desired (see Appendix C). Despite these 
resources being provided from a local Merck vaccine representative, these resources were 
not provided to all attendees nor was the educational opportunity sponsored by or in 
conjunction with Merck.  
Terms used to search included HPV and human papillomavirus, Gardasil or 
Gardasil 9-valent or Gardasil 4-valent, parental hesitancy, provider recommendation, 
immunization and vaccination, opposition or hesitancy, health belief model, theory, 
mandate and legislation. Articles searched were limited to articles published within the 
last 5 years and included both qualitative and quantitative studies exploring HPV 
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immunization. The evidence-based medicine pyramid, also known as the pyramid of 
nursing research hierarchy, was used to appraise the evidence by identifying high quality 
articles and identifying the highest quality literature recommendations in current practice. 
While appraising evidence that met criteria for inclusion, a large majority of qualitative 
data ranked significantly higher in the hierarchy of evidence, the quantitative data 
however tended to be of lower quality evidence. The quantitative data predominantly 
explored parental and provider rationales that were considered influential or discouraging 
in HPV immunization.  
My practice question sought to explore the relationships that exists between a 
parents’ perception of benefit of immunization and the provider’s recommendation. 
Supporting a presumptive recommendation, helps to increase immunization rates while 
providing more efficient and visit focused care (AAP, 2017). Many medical societies 
have endorsed HPV immunization in adolescents. Societies such as the ACOG, AAFP, 
AAP, and ACS are governing bodies that help identify the evidence that is behind the 
recommendation for immunization and aid in addressing the practice focus question.  
Applying current knowledge and understanding of HPV immunization to the 
teaching project helped clinicians to be better prepared in delivering the important 
message of cancer prevention. It also helped to ensure that the medical community is 
promoting lifelong population health. Enhancing provider knowledge not only allowed 
for more efficacious promotion of this immunization, it also helped them understand the 
impact of the lag in implementing this recommendation. 
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Appraisal of Evidence  
I appraised the documents found during my research and categorized them based 
on the evidence-based medicine pyramid, also known as the pyramid of nursing research 
hierarchy. Systemic reviews and meta-analysis received highest rating of evidence-based 
practice followed by evidence syntheses, critically appraised evidence, randomized 
control trials, cohort studies, case reports, and expert opinion. The literature search 
resulted in 54 articles of which 36 were specifically applied using the EBM Pyramid. The 
appraisal revealed two systematic reviews, two meta-analysis, two randomized control 
trials, 22 cohort studies, five case-controlled studies, and one background article. 
Inclusion criteria included peer-reviewed articles published in the last 5 years and 
included the following search terms: communication, discussion, approach, barriers, 
HPV or human papillomavirus, and parent, provider, or physician. After articles were 
selected for review, they were evaluated for scientific rigor using the evidence-based 
pyramid. I then analyzed recommendations from qualifying articles and applied them to 
the educational in-service.  
Evidence Generated for Doctoral Project. 
The teaching project educated providers on how to recommend HPV 
immunization within the outpatient setting. Using the new patient education approach not 
only incorporated recommendations for a change in practice found within current 
literature, it also included theoretical underpinnings from the HBM.  
The project team worked closely together through the completion of this project. I 
collected evidence-based recommendations and developed the teaching in-service. 
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Quantified evidence-based information was placed into a power point presentation and 
shared with the CMO. As part of the project team, the CMO critically appraised the 
information to ensure high-quality evidence-based recommendations were being 
translated to the attendees and into practice. The critiquing process helped to identify 
outliers and missing information, which was noted. The CMO provided permission for 
the educational project to occur within the healthcare system and approval from Walden 
University IRB for this project was attained. Once approvals were received, the in-service 
was placed on a schedule of monthly round table discussions.  
Attending round table discussions is an administrative role of each provider in the 
institution. Providers from outpatient clinics from all specialties use this time to stay 
abreast of evidence-based recommendations and learn about community resources and 
networking solutions that align to enhance patient care within the network and the 
community. Therefore, their attendance is strongly encouraged and realized. Round table 
events occur every 4 weeks and offer providers enhanced knowledge and understanding 
of commonly incurred practice topics. Round table events are focused on reiterating 
evidence-based practice guidelines and sharing valuable resources to providers that aid 
them in enhanced care delivery. Some round table events also offer continuing education 
credits, though this is not always the case and was not be the case with this educational 
in-service. 
Participants 
The target audience for this education activity included providers practicing in 
primary care, pediatrics, obstetrics and women’s health. During one of the regularly 
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scheduled monthly educational in-services providers were educated about information on 
how to standardize their recommendation for HPV immunization. Upon successfully 
educating providers on how to discuss HPV immunization with parents, immunization 
rates may increase to target goals set forth from ODPP. As a result, population health will 
be promoted, and HPV associated health care cost may be reduced.  
Procedures 
With project approval from Walden University’s IRB and with approval and 
delivery date from the institution’s CMO implementation of the doctoral project began. 
The educational activity followed Walden University’s educational manual. I worked 
with the project team to complete and deliver the educational opportunity for providers to 
learn about evidence-based approaches to recommending Gardasil 9 immunization to 
their patients. 
Once the date for the educational activity was scheduled, the administrative 
assistant and I used the hospital’s email server to invite all practicing providers to the 
monthly round table to attend this single educational in-service. This nonrandomized 
approach aligned with the standard method of inviting providers to this routine event. 
While many providers do not achieve 100% attendance for the round table, it is part of 
their job description to attend at least 80% of these functions; therefore, turnout is a 
favorable method of disseminating important practice changing information to the group. 
Invitations for round table are also sent to independent physician/nurse practitioner 
practices that have hospital privileges. Students observing providers may also attend 
round table if it falls during their clinical rotation.  
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Some providers replied to the email, while the majority show up without a 
reservation as their daily operational schedules allow. Once the providers came to the 
scheduled round table, they were asked to sign in. Lunch was served, and the introduction 
of the presenter began. After introducing myself as the project team leader and presented, 
I advised all participants of their right to opt out of participation at any time. They were 
instructed on evidence-based practice recommendations for discussing HPV 
immunization with their patients. The presentation was delivered live using power point 
slides to reinforce educational objectives as outlined in Table 1. Power point slides were 
also available in print for participants to take notes on and refer to once they returned to 
their clinical setting. The presentation lasted for 60 minutes, the standard meeting time 
for the monthly round table, and allowed for questions at the end of the presentation.  
Attendees were informed of the objectives of the presentation. Each objective 
sought to enhance provider knowledge and comfort of discussion of Gardasil 
immunization. The problem statement was delivered through discussion of looking at low 
HPV immunization rates at the institutional level, the state level, the national level, and 
the global level. The importance of the immunization was discussed focusing on key 
points that corresponded to the constructs of the HBM, as shown in Table 2. Providers 
learned about barriers that exists in discussing HPV immunization and learned about 
methods and approaches that will aid in countering resistance to the set recommendation. 
The literature review which was conducted prior to the educational intervention delivery 
graded recommendations using the evidence-based pyramid. A synopsis of the research 
gathered, evaluated, and graded was shared with attendees. This helped providers feel 
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comfortable in applying these practice-changing concepts at the bedside. Evidence that 
has been evaluated for scientific rigor with application of the levels of evidence pyramid 
was disseminated during the in-service. Information on how the pyramid ensures that 
only the highest quality recommendations from current literature was discussed and 
highlighted where each recommendation falls and was encouraged as a change in 
practice. The educational focus reiterated the importance of a strong recommendation by 
the provider as the single most influential factor to help promote immunization uptake. 
Teaching points for the educational in-service that align with the activity objectives and 
the HBM are reflected in Table 2.  
46 
 
Table 2 
Educational Intervention Discussion Points 
Objectives Health Belief Model Teaching Points  Emphasis 
Current HPV 
Metrics 
Perceived susceptibility 
 
Perceived severity 
Prevalence rates 
 
Frequency of infection 
 
Complications 
Cancer prevention 
Benefits of 
Immunization 
Perceived benefits Reduced morbidity and 
mortality. 
 
Reduce medical cost 
burden. 
Safety  
Barriers to 
Immunization 
Perceived barriers 
 
Perceived susceptibility 
 
Perceived severity 
 
Perceived benefits 
Parental uncertainty, time 
since debut, safety, not 
necessary, lack of value, 
missed opportunity, age 
recommended 
Cancer prevention 
 
Adolescent 
immunization 
 
Safety 
 
Efficacy 
Enhanced 
Knowledge 
Perceived susceptibility 
 
Perceive severity 
 
Perceived benefits, 
 
Perceived barriers, 
 
Cues to action 
 
Self-efficacy 
Prevalence 
 
Frequency 
 
Persistent infection 
 
Complications 
 
Cost 
 
Use of CASE 
Cancer prevention 
 
Adolescent 
immunization 
 
Safety 
 
Efficacy 
Improve 
vaccination rates 
Cues to action 
 
Self-efficacy 
Prevalence 
 
Frequency 
 
Persistent infection 
 
Complications 
 
Cost 
Use of CASE 
Cancer prevention 
 
Adolescent 
immunization 
 
Safety 
 
Efficacy 
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Each attendee was provided with a standardized assessment tool used by the 
hospital system to evaluate continuing education opportunities. Attendees were asked to 
evaluate the content delivered and determine if their knowledge base on the topic had 
increased and to evaluate if the learning objectives were met. The tool also evaluated the 
speaker’s presentation style, which will be analyzed for the purpose of this project but not 
considered an important project outcome. Permission for use of the institution’s standard 
continuing education evaluation tool was obtained. This instrument can be found in 
Appendix A. While the purpose of this project was to increase provider awareness and 
educate them on efficiently and scientifically recommending Gardasil 9 to their patients, 
providers who attended learned about evidence-based strategies on discussing HPV 
immunization that may help to enhance immunization rates with application. Future 
projects could evaluate the effectiveness of this educational in-service on practice.  
The findings from the educational session have the potential to be applied in 
various settings where immunizations are provided. Through successfully educating 
providers, this project has the potential to increase immunization rates and serve as an 
improvement project model that can affordably and efficiently reduce health care 
expenditure and promote adolescent and young adult health. This project served to better 
understand alternative methods to increasing immunization rates outside of a state or 
school mandate. 
Protections 
A convenience sample of health care providers were invited to attend the 
educational session; however, attendance was affected by clinical and personal schedule 
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demands. Written consents to participate were not required for this educational in-
service. There were no incentives afforded for project participation. Opening statements 
for the educational opportunity included a disclosure that the educational offering was an 
academic requirement for fulfillment of the project manager’s doctoral degree in DNP 
program at Walden University. They were again informed of the project approval by the 
institution’s CMO and the Walden University IRB. All participants were informed that at 
any time should desire to withdraw from the project before or during the in-service, they 
may do so. The evaluation tool has been kept confidential and participant names were not 
required. To further ensure confidentiality, there was no disclosure of the institution’s 
name.  
Following implementation of the project all evaluation tools were stored in a 
secured confidential location for the designated period of time per IRB criteria then 
destroyed. This project is not considered harmful to human subjects in any way as 
participants are being educated on current practice recommendations for adolescent 
immunization as supported by the CDC and ACIP.  
Analysis and Synthesis 
Improving healthcare does not mean that recommended evidence-based practice 
change is implemented without reviewing the literature, exploring the findings, and 
seeking to validate the proposed claims. In the educational project, evidence-based 
practice changes were promoted within the outpatient clinical setting within the context 
of existing literature recommendations. The project sought to enhance provider 
recommendations as an approach to validating similar studies exploring provider 
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recommendations and the influence on immunization uptake. The insights gained from 
this project further contribute to the existing knowledge of 9vHPV, as well as 
immunology in general. 
The continuing education evaluation form was entered into the hospital systems’ 
Survey Monkey to assist with analysis of the two data sets (appropriateness of the 
presentation and the standardized assessment tool- which evaluated the presentation). 
There are seven questions on the evaluation tool; responses for the first four questions 
were based on a Likert scale and responses for the last three questions were open-ended. 
Respondents were asked to grade the relevance of material, the quality of the speaker, the 
quality of handout(s), and their perception of increased preparedness on addressing the 
topic with patients following the educational opportunity using the likert scale with 
responses ranging from poor to excellent. Responses to open-ended questions helped me 
to identify consistent themes as they indicated what respondents liked the most and the 
least from the presentation. The final evaluation question asked about future programs 
and suggested a desired interest in additional information of the topic matter. Responses 
provided helped me to better understand if the participants increased their knowledge and 
found the information informative as well as important to practice.  
Analysis Procedures 
The data analyst assisted in reviewing and analyzing the data collected on the post 
educational program surveys. A data analysis system, Survey Monkey, was used to 
capture and analyze the data collected. Descriptive statistics were applied to analyze the 
results. Working together, the data analyst would have been able to assist the DNP 
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student in analyzing and synthesizing the project findings. This process provided the 
findings and implications of the educational project and helped to evaluate and 
recommend the need for future projects on HPV immunization. The data project findings 
and recommendations are further discussed in section 4. 
Summary 
Exploring the relationships between current immunization practices and 
guidelines for Gardasil 9 contributes to the current body of literature that seeks to 
understand the relationships between the two. While data trending reflects progress with 
HPV immunization, it is still far from desired vaccination goals set forth by Healthy 
People 2020. The goal of educating providers on methods of effectively promoting HPV 
immunization to the adolescent population was to improve population health and reduce 
wasteful spending. An educational project such as this not only identified current 
guidelines and recommendations, it also set the stage for future research projects around 
increasing HPV immunization in primary care. The educational project aligned with 
required learning objectives set forth by AACN that reflect doctoral scholarship. In 
section 4, findings from analysis of the educational activity and recommendations are 
discussed with a focus on limitations, outcomes, and implications for practice. 
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Section 4: Findings and Recommendations 
Introduction 
In Indiana, less than 10% of sixth graders have received immunization for HPV 
that matches ACIP guidelines (Indiana Department of State Health, n.d.). Nationally, 
HPV immunization target rates are set at 80% (ODPP, 2017); however, rates have been 
identified at roughly 40% (National HPV Vaccination Roundtable, n.d). There is much 
work to be done to increase immunization rates to the target goal. I sought to increase 
provider knowledge about holding conversations about Gardasil immunization in attempt 
to increase rates, thus addressing the current gap in practice. The practice question asked 
Did an education opportunity rooted in evidence-based practice enhance providers’ 
knowledge about how to have an effective conversation with adolescents and their 
parents about HPV immunization? Through a lunch and learn educational presentation, I 
sought to educate providers on enhancing their understanding by incorporating constructs 
from the HBM and effectively applying them to discuss HPV immunization with 
patients.  
Sources of Evidence 
The presentation consisted of a power point that included evidence-based 
information that reflected upon the following: Healthy People 2020 goals, current 
immunization data for adolescents, the importance of immunization, recognized barriers 
and recommendations to overcome these barriers as supported in current literature. The 
HBM was used as the theoretical underpinning for the project. Providers were educated 
on how to align constructs from the HBM with identified barriers when applying the 
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model to clinical practice and patient education. Additional resources developed by 
Merck the manufacturer of 9vHPV were available to attendees. These resources included 
recently updated prescribing information for clinicians, and educational resource for 
patient education.  Additional resources offered by entities other than Merck were also 
included to counteract bias. These resources were endorsed by the CDC, AAP, ACOG 
and AAFP. Each of these brochures, forms, letters, and pamphlets are available through 
the corresponding websites (CDC, AAP, and ACOG). These resources were selected as 
they reinforced the presentation’s teaching points and supporting literature while also 
providing providers with nonbiased information pertinent to prescribing.  
Findings and Implications  
Following approval from the Walden IRB committee and the hospital’s CMO, the 
educational project was drafted accordingly to comply with the educational manual at 
Walden University. The project team aided in scheduling the presentation as well as 
assisting in set up and project delivery. Providers that are employed by the hospital 
network and privileged at the hospital were invited to participate via email. Those in 
attendance were selected in a nonrandomized fashion, as daily operational schedules 
influenced attendance. There were 25 providers invited, with nine attending on the day of 
presentation. Of the nine participations in attendance, one participant had to leave during 
the presentation, resulting in eight completed continuing education evaluation tools. Two 
of the nine participants were late to the presentation but were easily brought up to speed 
as they had arrived after the introductory slides were delivered. They were advised of the 
project and their rights as participants.  
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Eighty-eight percent of the participants completed the continuing education 
evaluation tool following the presentation. The continuing education evaluation tool, 
which can be found in Appendix A, consists of seven questions. The first four questions 
are on a Likert scale with participants rating their response between one (poor) and five 
(excellent). The last three questions consist of open-ended questions, with inquiry about 
what the participant enjoyed the most and least about the presentation. The final question 
sought what topics are desired for future presentations.  All data collected from the 
continuing education evaluation tool was entered into the hospital’s Survey Monkey 
account for more detailed analysis. Question A, which asked about the practicality and 
relevance of the material found that all respondents felt that the information was 
excellent. Question B, asked about the quality of the speaker, all respondents felt the 
speaker was of excellent quality. Question C assessed the quality of the handout(s), 
which all respondents again rated as excellent. Question D sought to evaluate how well 
the program increased the participants knowledge on the topic. Eight of the nine 
participants rated this as excellent, with one participant rating this at a four out of five on 
the Likert scale or as very good. Figure 2 depicts the responses from the participants.  
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Figure 2. Continuing education evaluation tool responses on a Likert scale 
Questions E, F, and G were open ended questions and therefore do not appear on the 
graph above. Instead these questions were analyzed for themes. Question E asked What 
did you like most about this program? The following themes were collected for E: 
speaker knowledge, presentation and style, evidence driven, practicality, and hard copy 
of presentation. Two of the eight participants responded to Question F: What did you like 
least about the program. Both commented on difficulty of visualization of slides. One 
participant answered Question G: What topics would you like the program to offer in the 
future, stating “Further investigate older adults who get the vaccine (ages 26-45). Do 
their bodies ‘take’ the vaccine well?” Despite being very nervous and even terrified of 
public speaking, I found that I had a very generous audience that applauded my public 
speaking abilities and offered encouragement for future speaking opportunities, some of 
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which even went as far as to comment on their continuing education evaluation tools 
outside of the standard response sections.  
Unanticipated Limitations  
The participant turnout rate was significantly less than anticipated, at 36%. 
Despite the lower than anticipated attendance, the attendance was greater than the 
average attendance rate for round table which is usually between 24-32%. Despite the 
small sample size, the enthusiasm of the audience may have had a positive impact on the 
participants and subsequently the data collected. The questions and discussions that 
occurred during and immediately following the presentation reflected the importance of 
this educational intervention and allowed for a more engaging and interactive discussions 
around HPV immunization. The data yielded not only supports that providers learned 
additional information on how to enhance their conversations about 9vHPV 
immunization in adolescents, the conversations and questions of the presented data 
reflected that providers learned new information. One hundred percent of the participants 
found the information relevant to clinical practice; speaking to the importance of this 
topic. Following the end of the presentation, all providers in attendance were openly 
discussing how they approach recommending HPV to their patient populations and all of 
them agreed that once a parent has vocalized that they are refusing the vaccine during the 
office visit, any additional mention of the vaccine or counseling does cause a change in 
the emotion and tone in the room. Many agreed that pushing the issue with parents, 
regardless of how gently it is done causes them to further withdraw and liked the ideas of 
how they could approach the discussion during other exam opportunities that might not 
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poise the same resistance. Providers found discussing HPV and its cancer preventing role 
during dental checks, pap smears, and physical exams to be a great way to educate their 
patient panels outside of adolescent visits. As the presentation focused on adolescent 
immunizations, one of the participants had questions about how to overcome parental 
opposition and the consequences of letting parents elect to vaccinate later. This question 
was poised prior to reaching that discussion point during the presentation, however this 
participant felt strongly that in their practice area adolescent are not becoming sexually 
active early in their teens and that data was not an accurate reflection of local trends. 
They were receptive that this was an average across the United States, but still felt that it 
likely was not harmful to postpone immunization until later in adolescents when declined 
at the target age range. It did seem that discussion of the immune response before the age 
of 15 seemed to better reflect the importance of recommending 9vHPV regardless of the 
age of sexual debut. Providers then questioned if the immune response is better at 9 and 
10 years of age, why wait until 11 or 12 years of age to give the immunization. This did 
spark conversation among participants following the closure of the presentation, where 
others discussed approaches they have used and heard discussed in other venues, such as 
Focus on the Family, a Christian-based podcast. Some of the participants held onto the 
idea that they did not believe sexual debut was as early as 14 years of age locally, while 
others appreciated that defining sexual activity is difficult and hence getting an accurate 
reflection of debut poises yet another challenge. Furthermore, this discussion allowed for 
me to once again, emphasize that the focus of this vaccine really should be on its cancer 
prevention and not sexual transmission. 
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 At the participating institution, there have been recent changes that have moved 
the vaccines for children (VFC) program out of each office and to a centralized office 
within the hospital. This change followed policy changes at the state level that directly 
impacted the network. This change unfolded after the institution agreed to allow for the 
educational project to be delivered to their providers but before the presentation was 
finalized for delivery.  
Providers at the hospital were concerned that removing these immunizations from 
their office would allow for additional missed encounters for routine checkups and the 
process was modified so that VFC patients must be current on their well child or 
adolescent visit before presenting to the clinic for immunization. Providers therefore 
 still see and provide counseling on the immunizations due during an office visit. Parents 
of a VFC eligible child or adolescent must take their child to a different clinic for 
immunization, allowing for fall out following an appointment with a provider at an offsite 
location as well as a parent or guardian changing their mind before the immunization is 
provided.  
While participants working at the VFC identified clinic were invited to the round 
table, no one from that clinic presented on presentation day. This limitation not only 
affects individuals due for immunization, but also carries implications for the institution 
as a whole and extends into the community. Implications include lower than desired 
immunization rates in the organization and community, lost reimbursement for achieving 
metrics deemed as satisfactory to health and wellness promotion, and lastly inability to 
reduce preventable cancers in young adults. Those working at the VFC clinic may lack 
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knowledge of the evidence-based recommendations and fail to focus on the cancer 
preventing benefits of 9vHPV. Once the parent arrives at the clinic, they may ask 
additional questions and the individual providing the immunization who has not been 
educated on effective strategies could alter the decision to vaccinate. Failing to increase 
9vHPV immunization rates carries risk to the community from a public health stance. 
Given the percentage of adolescents that qualify for VFC immunizations, it is essential 
that the VFC clinic is aware of the current evidence-based recommendations. Providers 
being equipped in effectively discussing HPV also allows for parents to reconsider their 
choice between their primary care provider and reaching the VFC clinic. It is imperative 
that parents who are still heavily weighing the decision be counseled in the same 
evidence-based fashion. 
This is important to mention as this new process may inhibit immunizations being 
provided in a timely fashion despite providers being for immunization the same day, as 
supported in the literature. Offering 9vHPV the same way and same day as other 
adolescent immunizations is an approach endorsed by the CDC and the AAP. This 
workflow change does not impact all of the adolescents entrusted to providers within this 
network as commercial patients still are counseled on immunization during their visit and 
often provided the recommended immunization(s) the same day before leaving the office.  
Implications 
 Positive implications of this project include promoting social change by educating 
providers on how to discuss HPV immunization effectively in the primary care setting. 
While the presentation focused on evidence-based recommendations for immunization, 
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during discussion following the presentation providers shared ideas that they have found 
effective with their colleagues. Providers also learned about utilizing opportunities for 
routine visits (pap smears, dental complaints) to approach the importance of timely HPV 
immunization. Ideally, utilizing and evidence-based approach to discussion of 9vHPV 
will increase rates to target goals and reduce associated health care expenditures and 
improve public health.  
Recommendations 
 Discussing HPV immunization effectively requires that the provider first 
understands what barriers exists and how to overcome those barriers. Providers in 
attendance learned that how the recommendation for HPV immunization is made matters, 
which has been supported by literature as the most crucial factor over and over. They 
learned that their recommendation was the single most effective strategy to increasing 
timely HPV immunization. They also learned how to refocus questions about HPV 
immunization and infection from sex to that of cancer and do so concisely and efficiently 
with little interruption in their standard approach for recommending immunizations. 
Approaches supported in evidence, including a presumptive recommendation and a 
presumptive recommendation using the sandwich technique were also discussed with the 
participants. 
While the continuing education evaluation tool did not specifically assess key 
objectives, this was outlined as an objective during the opening of the educational 
intervention. Understanding why parents or guardians opposed the immunization allowed 
for discussion that addressed their concerns and also provided opportunity for providers 
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to validate the importance of the vaccination. By refocusing the conversation on cancer 
prevention and elaborating on why it is recommended in adolescents’, as done during the 
presentation and immediately following, during discussion, providers could approach the 
conversation with confidence and enhanced parental receptivity. Providers learned that a 
presumptive recommendation is supported in literature as an effective means of 
recommending 9vHPV. However, they also learned that while using that technique they 
could build their recommendation on the constructs outlined in the HBM (susceptibility, 
severity, perceived benefits, perceived barriers, cues to action, and self-efficacy). 
Approaching conversations about HPV in this manner allowed providers to discuss the 
most important barriers in an evidence-based manner, which in turn addressed the current 
gap in practice.   
The HPV Vaccine Toolkit (AAP, 2019) has many resources for providers with a 
desire to increase HPV immunization within their practice setting. The toolkit includes 
nicely compiled recommendations endorsed by various organizations and Merck and are 
supported within the context of this project. Another resource, which was made available 
and serves as a secondary resource was published by the CDC (2018c) and can be found 
in Appendix C. This infographic reflects the recommended immunization schedule for 
children as young as 7 years of age and adolescents up to 18 years of age. It also supports 
that while 9vHPV can be given at 9-10 years of age in “high risk” individuals, it can also 
be provided if desired by the parent at that age as well and is considered a ‘catch up’ 
immunization after 13 years of age.  
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Contribution of the Doctoral Project Team 
Process 
The project team was supportive throughout the project; however, team 
interactions and overall support were more limited than expected, which could have been 
due to the administrative duties of members and the independent scholarship role of the 
DNP student. The data analyst was pivotal in validating the benefit of a teaching 
intervention at this institution. He was able to analyze existing data and support the value 
of the project. The data analyst offered continued support of this independently created 
DNP project. The CMO approved the project, overall, and also provided feedback and 
final approval of the in-service prior to it being scheduled. Support staff was pivotal in 
scheduling the presentation and inviting providers. Together all team members supported 
the project development and helped in facilitating the educational presentation. While the 
data analyst’s assistance was limited in the post implementation phase, guidance was 
offered, and the DNP student was able to effectively analyze the data and resulting 
outcomes.  
Plans 
First and foremost, I plan to reach out to the pediatric office that is affiliated with 
the hospital network to introduce and possibly schedule time to present my project to 
their office personnel given that the VFC clinic is part of their clinic operations and that 
they may potentially serve the largest target population.  I also plan to further disseminate 
my project findings at the local level, by applying to present my DNP project at the 
annual Coalition for Advanced Practicing Nurses of Indiana (CAPNI) meeting in the 
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spring and submitting to the Journal of Nurse Practitioners as part of their DNP project 
submissions.  
Strength and Limitations of the Project 
Strengths 
 Addressing HPV immunization is well supported as an important health objective. 
Strengths of this project included a thorough evaluation of the existing literature on HPV 
immunization, which supported the need for additional research given the limited 
numbers of systematic reviews and meta-analysis that exist on the topic. There is a need 
to build on the existing literature in order to develop more substantiating research 
projects that help better define how to overcome the barriers regarding HPV 
immunization. The presentation was developed using evidence-based practice 
recommendations from current literature on communication strategies on HPV 
immunization.  Despite the small sample size, 100 percent of the participants found the 
material relative to their practice and nearly all felt that their preparedness on the topic 
was enhanced, further supporting the need for similar projects. The findings also suggest 
that delivery of this project in alternative venues such as in a dental office, health 
department, shot clinic, or school system may also result in enhanced knowledge of how 
to discuss HPV immunization effectively with parents of adolescents. With the newest 
recommendation to extend 9vHPV immunization to unvaccinated males and females up 
to the age of 45, this project could be replicated looking at the young adult population’s 
immunization status to continue educating providers on how to recommend 9vHPV in the 
same or similar settings. Local, national, and global immunization rates that have been 
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inadequate are slowly improving population health in those whom are unable to get 
regular health screenings (CDC, 2013b). Retrospective studies have already begun to 
document decreased prevalence rates of the diseases associated with persistent HPV 
infections (CDC, 2013b). I found that despite my overwhelming anxiety of public 
speaking, participants found my presentation style to be engaging, which helped to boost 
my confidence in presenting my findings outside of the network.  
Limitations 
 The small sample size was a limitation as well as a strength. Having a larger 
audience likely would not have suggested that everyone would have found the 
information to be relevant or enhanced their preparedness. However, having a smaller 
audience did allow for engaging conversations, which helped to further refocus and 
emphasize the importance of discussing this vaccination as one of cancer preventing. The 
networks decision to remove VFC from their clinics and locate it centrally also serves as 
a limitation of this project. Centrally relocating the VFC clinic occurred after the project 
development had started and the focus was to educate the outpatient clinic providers on 
how to effectively discuss HPV immunization. This limitation was further magnified by 
the absence of the clinicians from the VFC clinic during the scheduled round table.  
Despite evidence-based practice recommendations to use a presumptive 
technique, I believe this communication tactic serves as a potential limitation.  
Communication that uses a presumptive recommendation with the sandwich technique, 
could be perceived as deceptive by parents. Parents who hear Tdap and Menactra but 
miss the recommendation for HPV tucked in the middle, may further develop mistrust 
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with their provider’s recommendations for health maintenance. Though this technique 
has been validated as a successful strategy, I proposed that providers follow up the 
sandwich technique with mention of when the adolescent will need to return to complete 
the recommended series. Merck has funded many of the research articles that encourage 
application of the presumptive recommendation with the sandwich technique. Merck 
being the sole manufacturer of 9vHPV, funding a large majority of the existing literature, 
and encouraging concise communications through application of the CASE acronym also 
reflects their vested interest in the immunization and serves as a significant limitation. 
The CDC (2018d) and AAP (2017) simply encourage providers to use a presumptive 
recommendation, meaning that the recommendation for HPV be made just as they would 
recommend Tdap or Meningococcal immunization. The novelty of 9vHPV still causes 
parents to raise concerns about the safety and efficacy of the immunization. When 
questions arise, parents should be informed concisely about the benefits of HPV 
immunization surrounding cancer prevention (AAP, n.d.a; CDC, 2013a). The lack of 
systematic reviews and meta- analysis reflects a clear limitation in the current evidence, 
as overcoming the communication barriers has not yet clearly been reflected. There are 
many studies that are qualitative in nature and still exploring why 9vHPV has not been 
widely accepted and immunization rates have not reached the 80% target goal. There are 
very few quantitative studies that quantify the true and potential benefits of this 
immunization. This limitation also serves as a strength, supporting the premise of this 
project and the additional information that the project provides.  
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Recommendations 
 Recommendations for future scholarship include building upon this project and 
educating all providers and clinical staff within the healthcare system of the evidence, 
while analyzing data prior to and after and looking for increased immunization rates 
within the institution. Building on the current DNP project would add to the existing 
literature and help to validate the relevance and importance of HPV immunization, the 
very foundation of this project and bridge the gap in knowledge about HPV 
immunizations.  
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Section 5: Dissemination Plan 
Following approval from Walden University, this manuscript will be published in 
ProQuest. Following fulfillment of the DNP program at Walden University, I plan to 
submit my manuscript to the Journal of Nurse Practitioners as part of their DNP 
publication initiative, as well as present my findings via a poster presentation at the local 
CAPNI conference or potentially brave a speaking presentation where I would share and 
educational opportunity with the conference attendees in a similar format as that of the 
educational presentation delivered in fulfillment of DNP requirements. It may also be 
effective for dentists to discuss the importance of HPV vaccination during their 
encounters, as this would focus on the cancer prevention aspects of 9vHPV. I therefore 
may even reach out to local dentist to see if they would like to learn more about this 
connection and see what opportunities I would have to share my evidence with their 
profession. 
Analysis of Self 
As I reflect on the journey of this project as a practitioner, I am amazed at the 
breadth and depth of knowledge I have gained about the topic of HPV immunization. 
Even my understanding of vaccines, their history, and their contribution to population 
health has expanded significantly. While I started this project seeking to complete the end 
goal of attaining a terminal degree in the field of nursing, I wanted to pursue a topic that I 
felt was important as a mother and scholar. What I have learned over the course of this 
program has changed my personal and professional opinions of the importance of 
vaccinations and their impacts on population health. As I encounter parents who are 
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skeptical about the safety and efficacy of the HPV vaccine, I am confident that I can 
listen to their concerns and competently educate them on why timely immunization is 
essential for all vaccines.  
As a scholar, I have come to value the importance of a high-quality data driven 
study rooted in evidence. It is crucial to understand how data is displayed and what 
message(s) are being projected in research, so that low quality evidence does not dictate 
practice. While I faced challenges searching for and organizing literature, I also 
possessed new found strengths and the ability to critically evaluate the literature.  The 
knowledge I have gained helps guide scholars such as myself in not hastily implementing 
low quality research into practice.  
I have learned that scholarship is a dedication to lifelong learning that requires 
curiosity, knowledge, persistence, flexibility, and adaption even amidst challenges and 
fatigue. Working towards completion of my DNP reflects my commitment to lifelong 
learning and my profession. Even as I faced adversities throughout my DNP project, I 
held onto what lifelong scholarship means to me and today I have learned that each of 
those challenges has shaped me into the scholar I am today. As a project manager, I 
realized that I have the capability to identify a practice problem, address it with 
scholarship, and lead a project with purpose. I developed the DNP project based on a 
problem that I identified and am passionate about. I researched HPV immunization and 
infection extensively before creating a proposed solution to address the problem. I 
learned the value of working with a team. A team is needed in order to effectively 
address a practice problem. The members of the team aid in clearly identify the practice 
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problem, researching the topic, developing a solution, evaluating the process, and 
critically appraising the collected information before disseminating   
Scholarship and evidence help to bridge the gap that exists between literature and 
practice and enhance patient care. I feel equipped in pursuing the scholarship role more 
actively in the future and have gained much insight regarding how to handle challenges 
and adversities that exists within the scholarship role. This project will serve as a 
reminder that all things worth pursuing poise their own independent challenges, yet with 
persistence and faith all things are possible. My future goals include challenging myself 
to publication of my research outside of my collegial experience. I also hope to present 
my research during the upcoming CAPNI conference in spring of 2020.  
Completion  
I faced many adversities over the course of my DNP Project. The first presented 
itself early on when my project was not feasible for the setting I was in or the project 
type. As the project took shape, I became overwhelmed with the amount of data I had 
collected and attempted to organize, yet I still lacked a feasible project to implement. As I 
closely worked with my chair, life happened and poised its own challenges. I struggled to 
secure a facility that would grant me permission to carry out my DNP project and I 
continued to struggle to define my project. After months of communication with my 
chair, my project finally started to develop and subsequently became a feasible project 
that I could implement, despite the fact that I would have to deliver an oral presentation 
to a group of providers with my relentless fear of public speaking. Just as my project 
developed and I found a network that agreed to allow me to implement and complete it, a 
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merger was announced and poised further delays to completion. I felt as if I was racing 
the calendar and losing gained ground quickly. As I continued to work towards 
implementation, the hospital system announced changes to their VFC program due to 
regulatory changes beyond their control. These changes, no doubt, also would ultimately 
impact my project outcomes. By the grace of God and with a timely IRB approval, I 
delivered my educational project at the last roundtable before the merger started to 
impact operations. Just weeks before my project implementation, my project team also 
unexpectedly changed; one of the team members accepted a job outside of the 
organization.  My chair was crucial in assisting me as challenges presented reminding me 
that lifelong learning often is not without challenges or adversities. She calmly 
encouraged me to continue to persevere despite the challenges I faced and even 
encouraged me to rest as she sensed the fatigue and frustration. 
Thankfully given all of these challenges, with the help of my DNP chair and 
committee and my project team members I successfully implemented, analyzed, and 
finalized the project. Each of these challenges paired with everyday life stressors further 
reinforced that scholarship is an outcome that requires persistence, flexibility, adaption, 
determination, and faith. Doctoral work was uniquely different from previous works 
completed at the undergraduate level; it required more stamina than I knew I had.  
Summary 
 While HPV infection is thought to be a relatively benign infection given its 
asymptomatic nature and the body’s ability to clear the infection, it has a lifetime 
prevalence of up to 100% and is attributed to 5% of the cancers worldwide. Immunizing 
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adolescents before sexual debut is crucial to reducing the prevalence of this virus but also 
the disease burden associated with persistent or high-risk infection.  
 Providers are essential in delivering the message about 9vHPV. Their 
recommendation matters more than any other factor influencing immunization. It is 
important to listen to the concerns our patients share, but it is equally important to equip 
them with the knowledge to make an informed decision for their health. While a 
presumptive recommendation for HPV is supported in the literature, we must overcome 
barriers that currently exists as we attempt to promote 9vHPV in adolescents. 
 Educating providers on how to effectively discuss HPV immunization within the 
primary care setting was perceived as beneficial and important to their ability to make a 
strong recommendation for 9vHPV. The continuing education program evaluation 
reflected that the information was perceived as relevant and helpful in increasing provider 
knowledge on the subject matter. A project such as this is not only easy to implement it is 
affordable and potentially carries great value to clinical outcomes. Increasing the sample 
size would have been beneficial in strengthening the project; however, the project still 
provided valuable insight and reflected that there is a significant need to refocus 9vHPV 
on cancer prevention versus sexual transmission even among providers.   
 Just as scholarly work requires effort and persistence, addressing inadequate 
immunization rates will also require effort and persistence from the nursing community. 
Providers need to be comfortable thinking of both conventional and unconventional 
approaches to help improve population health as well as looking to what evidence exists 
that can be built upon to strengthen the current problem. When discussing HPV 
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immunization with parents of adolescents, understanding that there is a great deal of 
information available to help validate their concerns as well as practitioner concerns is 
essential. As a team, we can increase rates towards the goal of 80% set forth by Healthy 
People 2020, which can improve population health and support the Walden the mission 
of social change. 
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Appendix A: Continuing Education Evaluation Tool 
 
 
 
 
 
 
 
 
 
 
Please rate the following to help in the development and improvement of CME programs. 
Poor  Good  Excellent 
A: Practicality/relevance of material  1 2 3 4 5 
B: Quality of speaker          1 2 3  4 5 
C: Quality of handout    1 2 3 4 5 
D: How well did this program increase   1 2 3 4 5 
your preparedness on the topic? 
E: What did you like most about this program? 
 
F: What did you like least about this program? 
 
G: What topics would you like the program to offer in the future? 
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Appendix B: Power Point Teaching Tool 
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Appendix C: Teaching Tools Provided for Providers During Inservice  
 
 
 
 
 
 
 
 
Give a strong recommendation for HPV vaccine to increase 
uptake! 
Dear Colleague: 
The American Academy of Family Physicians (AAFP), American Academy of Pediatrics (AAP), 
American College of Obstetricians and Gynecologists (ACOG), American College of Physicians 
(ACP), the Centers for Disease Control and Prevention (CDC), and the Immunization Action 
Coalition (IAC) are asking you to urge your patients to get vaccinated against human papillomavirus 
(HPV). 
HPV vaccine is cancer prevention. However, HPV vaccine is underutilized in our country, despite 
the overwhelming evidence of its safety and effectiveness. While vaccination rates continue to 
improve for the other adolescent vaccines, HPV vaccination rates have not. Missed opportunities data 
suggest that providers are not giving strong recommendations for HPV vaccine when patients are 11 
or 12 years old. The healthcare provider recommendation is the single best predictor of vaccination. 
Recent studies show that a patient who receives a provider recommendation is 4—5 times more 
likely to receive the HPV vaccine. 1 ,2 
What you say, and how you say it, matters. A half-hearted recommendation to a patient may not only 
result in the patient leaving your practice unvaccinated, but may lead the patient to believe that H PV 
vaccine is not as important as the other adolescent vaccines. The undersigned organizations hope that 
this letter, which provides key facts about HPV vaccine safety and effectiveness, will lead you to 
recommend HPV vaccination — firmly and strongly — to your patients. Your recommendation will 
reflect your commitment to prevent HPV-associated cancers and disease in the United States. 
HPV-associated disease 
 Approximately 79 million persons in the United States are infected with HPV, and 
approximately 14 million people in the United States will become newly infected with HPV 
each year. 
 Each year, an estimated 26,000 cancers are attributable to H PV; about 17,000 in 
women and 9,000 in men. 
 Cervical cancer is the most common HPV-associated cancer among women, and 
oropharyngeal cancers are the most common among men. 
 Despite these statistics, the use of HPV vaccination to prevent HPV infection is limited and 
immunization rates remain low. 
Prevention of H PV-associated disease by vaccination 
 Two vaccines (bivalent/HPV2 and quadrivalent/HPV4) are available to protect against H 
PV 16 and 18, the types that cause most cervical and other anogenital cancers, as well as 
some oropharyngeal cancers. 
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The American College of 
Obstetricians and Gynecologists 
WOMEN'S HEALTH CARE PHYSICIANS 
Coding Information on 
HPV Vaccination 
CPT Codes for Vaccine Administration 
  Route of   
Code Method Administration Type of Service Reporting Rules 
90471 Injection Percutaneous, 
intradermal, 
subcutaneous, or 
intramuscular 
primary Report only one primary vaccine 
administration per encounter. 
 
+90472 Injection Percutaneous, Additional Report for secondary or 
intradermal, subsequent vaccine administration. subcutaneous, or
 Report only with code 90460, intramuscular 90471 , or 90473. 
 
90460 Any route Percutaneous, primary Report only one primary vaccine intradermal, administration 
per encounter. subcutaneous, or Physician or other qualified intramuscular health care 
professional also provides counseling. 
Patient is 18 years or younger. 
 
90461 Any route Percutaneous, Additional Report for each additional intradermal,
 component in a vaccine subcutaneous, or administered in conjunction with 
 intramuscular 90460. 
Physician or other qualified 
health care professional also 
provides counseling. 
Patient is 18 years or younger. 
HPV Vaccines Administered to Adolescents and Adults 
 Code for CPT Administration 
Vaccine Vaccine Product Code 
90649 90460-90472
(nonvalent [9vHPVl) a-dose schedule, intramuscular 90651 90460-90472 
 
Abbreviation: HPV, human papillomavirus. 
This information is provided by the American College of Obstetricians and Gynecologists for educational purposes only. It 
is not intended to represent the only, or necessarily the best, coding format or method for the situations discussed, but 
rather as an approach, view, statement, or opinion that may be helpful to persons responsible for diagnosis and procedure 
coding. The statements made in this document should not be construed as the American College Of Obstetricians and 
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CDC Provider How to Discuss HPV Vaccines found at https://www.cdc.gov/hpv/hcp/for-
hcp-tipsheet-hpv.pdf 
 
Changing the Future: Preventing HPV Cancers found at https://www.aap.org/en-
us/Documents/COMP-ChangingTheFuture.pdf 
 
HPV Vaccines are Safe Here’s How We Know found at https://www.aap.org/en-
us/Documents/AAP_Fact_Sheet_Vaccine_Safety_LR.PDF 
 
HPV Vaccination Just the Facts found at https://www.aap.org/en-us/Documents/HPV-
Vaccination-Just-the-Facts-for-Parents.pdf 
 
Take a Shot at Cancer found at https://www.aap.org/en-us/Documents/Parent-
Handout_Take-a-Shot-at-Cancer.pdf 
 
HPV is Cancer Prevention Toolkit found at https://www.aap.org/en-us/advocacy-and-
policy/aap-health-initiatives/immunizations/HPV-Champion-Toolkit/Pages/The-
National-HPV-Vaccination-Roundtable.aspx 
 
 
 
